



September 27, 2021

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

## **Announcement of Receiving Manufacturing and Sales Approval for biosimilar in the Ophthalmic Area in Japan**

Tokyo, September 27, 2021 – Kidswell Bio Corporation. (“KWB”) has been collaborating with Senju Pharmaceutical Co., Ltd. based on the joint development agreement for the biosimilar in the ophthalmic area (Project name: GBS-007) executed on May 12, 2016, and Senju Pharmaceutical Co., Ltd. has received approval of manufacturing and sales in Japan from the Ministry of Health, Labour and Welfare on September 27, 2021.

It is the third product to launch in the biosimilar business following Filgrastim BS and Darbepoetin Alpha BS. Besides the revenues from these biosimilars, by leveraging the know-how and expertise about biotechnology acquired in the past business activities, we will continue focusing on the accomplishment of the medium-term strategic plan and further business growth.

The impact on the business results for the fiscal year ending March 2022 has already been incorporated into the initial plan, and there are no revisions to the financial forecast at this time.

### About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which GTS has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential vital force such as SHED and CSC, we envision creating new pharmaceuticals and therapeutics for all people under “Kids Well, All Well.”

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: [info@kidswellbio.com](mailto:info@kidswellbio.com)